Loading…
Loading…
PLUR does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for PLUR and 80,000+ other tickers.
See exactly how PLUR's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for PLUR and 80,000+ other tickers.
Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology. A key candidate, PLX-PAD, is in advanced clinical development, with ongoing Phase III trials for muscle recovery after hip fracture surgery, Phase II studies for acute respiratory distress syndrome associated with COVID-19, and Phase…
Plurilock Security Inc. (PLUR:CA) Discusses Corporate Update and Growth Strategy in Defense Contracting Portfolio Transcript
Pluri's majority-owned food-tech company adds aquatic cell biology, animal-component-free media capabilities and a European scientific presence Pluri's majority-owned food-tech company adds aquatic cell biology, animal-component-free media capabilities and a European scientific presence
UK regulatory registration supports commercial launch of regenerative aesthetics portfolio in a marke t with an estimated size of ~$900 million annual ly , an d strengthens the foundation for broader international expansion HAIFA, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR), a biotechnology company pioneering 3D cell-expansion technology to power scalable cell-based products across therapeutics, regenerative aesthetics, longevity and agri-food tech, today announced that its consumer-health and aesthetics subsidiary, Cellav Health and Aesthetics Ltd. ("Cellav"), has successfully completed the cosmetic regulatory registration and notification process in the UK, supporting a coming commercial launch of its regenerative aesthetics product, Regenativo+, marking another significant milestone in the Company's commercialization strategy.
Vancouver, British Columbia--(Newsfile Corp. - June 16, 2026) - Plurilock Security Inc. (TSXV: PLUR) (OTCQB: PLCKF) ("Plurilock" or the "Company"), a services-led, product-enabled, AI-native cybersecurity company, is pleased to announce the results of its Annual General Meeting (the "Meeting") of shareholders held on June 16, 2026. All resolutions presented to the shareholders were approved.
Two regenerative aesthetic and longevity products, with clinically validated ingredients , are expected to reach the U.S. market during 2026, entering a rapidly expanding U.S. medical aesthetics market, projected to reach $90 billion by 2030 HAIFA, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ: PLUR) (TASE: PLUR), a biotechnology company pioneering 3D cell-expansion technology to power scalable cell-based products across therapeutics, regenerative aesthetics, longevity and agri-food tech, today announced that its consumer-health and aesthetics subsidiary, Cellav Health and Aesthetics Ltd. (“Cellav”), has completed the development and U.S. cosmetic product listings of two flagship regenerative aesthetic products - Regenativo+ and Placento+, clearing the path for commercial launch in the United States.